BBUC is Brookfield Business Partners' C-corp wrapper. Q1 2026 earnings (May 8) put a distressed position front and center — and management chose not to mark it.

What the filing said

Q1 adjusted EBITDA $582M, +5% organic, $2.4B pro-forma liquidity, $285M of buybacks deployed since the Feb 2025 NCIB launch. Clarios (≈30% of NAV, ≈$15/unit contribution at BBU level) received $1.0B FY2025 critical-minerals tax credit in March. Management laid out explicit 5-year math: LTM EBITDA $2.3B growing to $3B+, 9-10x multiple, ≈$30B EV, $8B cash generation taking net debt from $11B to ≈$4B — projected equity value $26-27B, doubling the Clarios contribution to ≈$30/unit. FY2024 credit (≈$1B) "still under processing at the IRS"; CFO would only confirm "no feedback to indicate the refund should not be coming."

Sagen mortgage insurance loss ratio doubled to 12% from a ≈5% historical baseline (2022-23 high-LTV vintage stress; Canadian house prices -20% from 2022 peak). MICAT capital ratio 182% vs 150% minimum; $400M annual distribution capacity preserved. La Trobe Financial 27% partial sale to Axight at $2.1B valuation announced April 17 — 3x MOIC, 35% IRR over <4-year hold. Corporate simplification completed end-March; +40% trading volume; ≈5M shares of expected index-rebalancing demand.

On CDK Global (auto dealer management software, taken private 2022 with GIC at $8.3B), prepared remarks said only "contractual annual price increases." When analyst Scott Fletcher asked about bonds pricing equity near zero, CFO Jaspreet Dehl recited a generic distress playbook, named the Altera workout (where Brookfield admitted "the majority of our capital" was returned — i.e., partial loss), and closed with "not specific to CDK or any other situation today."

What the market thinks

BBUC -5% on the week, BBU -8%, BAM flat. CDK first-lien loan fell from ≈84c (mid-January) to 61.2c (mid-April), with a Gibson Dunn-advised creditor cooperation pact in place. NAV bridge ex-CDK is ≈$31-34 per BBUC unit using management's Clarios contribution and the Axight-implied La Trobe stub. Current price sits near base-case NAV. Market is pricing CDK toward zero — but not punishing the silence.

Why the gap

Two specifics. First, LAD and ABG — two of the three largest US franchise auto retailers — publicly disclosed CDK exits on April 28-29, nine days before BBUC's call. LAD bought out its contract and is deploying Pinewood across ≈300 NA stores. ABG won an October 2024 preliminary injunction forcing CDK to enable Tekion data transfers; converted dealerships are showing +21% YoY gross dollars per technician. None of this surfaced in BBUC's prepared remarks or Q&A.

Second, BBUC's idiosyncratic variance runs at ≈35% (beta 1.38). The rest is market and sector factor exposure. The vehicle is not a clean expression of the thesis — sell-side may see the CDK pricing gap and still struggle to construct a trade in BBUC itself. The cleanest cross-ticker beneficiary is Pinewood (PINWF, UK micro-cap) but liquidity blocks institutional sizing.

Risks (ranked)

1. CDK survives at residual equity value — bondholder cooperation pacts sometimes yield out-of-court restructurings that preserve some equity
2. Clarios 45X policy risk — Trump-administration IRA review (ENS flagged "current administration priorities" delaying its lithium plant); FY2024 Clarios credit still unconfirmed at IRS
3. Canadian unemployment shock pushes Sagen above the long-run 15-20% loss-ratio target band, forcing a distribution cut
4. Market drawdown — beta 1.38 means factor exposure dominates short-horizon return on any portfolio sized to the idio thesis

Catalysts

• 2026-08-01 to 08-15 — Q2 2026 earnings; primary CDK writedown window
• 2026-09 (Q3) — La Trobe Axight expected close, ≈$1/unit cash
• 2026-09-30 — Sagen Q2 loss ratio print
• 2026-11-15 — Q3 2026 earnings; CDK writedown deadline; Clarios FY2024 IRS receipt window

What would change our mind

• BBUC files 8-K disclosing CDK impairment ahead of Q2 — confirms the thesis and defines the entry
• BBUC's Q2 10-Q reveals CDK already carried at zero or near-zero — mark was already taken, no further gap
• Clarios FY2024 credit rejected or materially delayed — weakens the bull anchor
• A third top-10 US auto retailer publicly announces CDK exit — accelerates timeline
• CDK strategic alternatives announced at premium to bond levels — bonds were over-discounted

Evidence